CBG - what is it? Complete guide to cannabigerol

Cannabigerol, abbreviated as CBG, still remains in the shadow of its more popular “cousins” - CBD and THC. This is somewhat paradoxical because without CBG, neither of these two compounds would form in the cannabis plant at all. Its acidic form, CBGA, is the biochemical matrix from which plant enzymes build all other main cannabinoids before the plant matures. Scientists described this molecule already in 1964, but for the next four decades it remained in the shadow of research on THC and CBD, mainly because it occurs in trace amounts in typical plants. This article explains what CBG is, how it was discovered, how it differs from CBD and THC, its potential therapeutic properties, and what you should know before buying CBG oil in Poland.

KEY INFORMATION
• CBG oils cost 2-4 times more than CBD because CBG constitutes below 1% of the plant’s dry mass ([Calapai et al., MDPI Medical Sciences](https://www.mdpi.com/2076-3271/10/3/47), 2022).
• CBG is non-psychoactive - weak affinity to CB1 receptor means no “high”.
• The first isolation of CBG was described in 1964 by Yehiel Gaoni and Raphael Mechoulam.
• In Poland, CBG products are legal if the sum of delta-9-THC and THCA does not exceed 0.3% (Dz.U. 2022 poz. 763).

What is CBG and why is it called the “mother of cannabinoids”?

CBG, or cannabigerol, is a non-psychoactive phytocannabinoid that in the living cannabis plant serves as a biochemical precursor. Its acidic form, CBGA, is the substrate for three synthase enzymes: THCA, CBDA, and CBCA. From this single compound, three main cannabinoids are formed ([Calapai et al., MDPI Medical Sciences](https://www.mdpi.com/2076-3271/10/3/47), 2022).

In practice, this means that the older and more mature the plant, the less CBG remains in its tissue - enzymes convert CBGA into THCA or CBDA, which after decarboxylation become THC and CBD respectively. Hence the typical CBG content in classic cannabis strains: below 1% of the flower’s dry mass, often closer to 0.1-0.3%. CBG does not cause intoxication: it has very weak affinity to the CB1 receptor responsible for THC’s psychoactive effects, and in vitro studies show it acts rather as a partial antagonist, weakening THC’s effect. The term “mother of cannabinoids” is informal, used by producers and patients - it stems from the fact that CBGA is the first full cannabinoid formed in the plant from olivetolic acid and geranyl pyrophosphate, and everything else derives from it.

CBG is a non-psychoactive phytocannabinoid that occurs in the living plant as CBGA - the precursor of three main cannabinoid synthase enzymes. Typical CBG content in standard cannabis strains does not exceed 1% of dry mass ([Calapai et al., MDPI Medical Sciences](https://www.mdpi.com/2076-3271/10/3/47), 2022).

When was CBG discovered and who was behind it?

The first isolation of cannabigerol was described in 1964 by Yehiel Gaoni and Raphael Mechoulam, two Israeli chemists from the Weizmann Institute (Gaoni and Mechoulam, Proceedings of the Chemical Society, 1964). The same Mechoulam published in the same year a paper on the isolation and structure of THC, and in subsequent decades discovered anandamide - the first known endocannabinoid produced by the human body.

The 1964 paper presented the structure of the CBG molecule and the method of its isolation from hashish. For the next four decades, however, CBG remained on the margins of mainstream research because typical cannabis samples contained much more THC and CBD, which attracted scientists’ attention. The situation began to change after 2015, when three factors coincided:

• breeders created “high-CBG” strains with CBG yields reaching 15-18% of the flower’s dry mass;
• CO2 extraction and distillation technologies became cheaper;
• research on endocannabinoids accelerated, and CBG proved to have unique mechanisms of action.

Cannabigerol was first isolated from hashish in 1964 by Yehiel Gaoni and Raphael Mechoulam from the Weizmann Institute in Israel (Gaoni and Mechoulam, Proceedings of the Chemical Society, 1964).

How is CBG formed in the cannabis plant step by step?

CBGA biosynthesis occurs in glandular trichomes - microscopic hairs covering cannabis flowers and leaves. Olivetolic acid combines with geranyl pyrophosphate under the influence of the CBGA synthase enzyme, producing cannabigerolic acid. This is the “zero moment” in the cannabinoid chain ([Calapai et al., MDPI Medical Sciences](https://www.mdpi.com/2076-3271/10/3/47), 2022).

Then CBGA, depending on the plant’s genetic profile, undergoes the action of one of three enzymes: THCA synthase converts it into tetrahydrocannabinolic acid, CBDA synthase creates cannabidiolic acid, and CBCA synthase produces cannabichromenic acid. These three pathways compete for the same substrate, so “high-THC” strains have little CBD, and “high-CBD” strains have little THC. Breeders discovered that by selecting plants with mutations in genes encoding these synthases, they can create a “bottleneck” in the biosynthesis pathway: the plant still produces CBGA but lacks enzymes for further conversion, so CBGA accumulates in trichomes up to 18% of dry mass. The most CBG is found in the plant around weeks 6-8 of flowering, well before maturity - standard breeders harvesting at weeks 10-12 “lose” much CBG to THC and CBD, while high-CBG breeders harvest earlier, consciously stopping conversion.

How does CBG differ from CBD and THC?

These three cannabinoids share a common molecular core - resorcinol with a ten-carbon geranyl side chain - but small structural differences translate into completely different pharmacological effects ([Calapai et al., MDPI Medical Sciences](https://www.mdpi.com/2076-3271/10/3/47), 2022). THC has a closed pyran ring, which gives it psychoactivity and strong affinity to CB1. CBD has an open ring and acts mainly outside the cannabinoid system, targeting receptors such as 5-HT1A and TRPV1. CBG also has an open chain but differs from CBD by two double bonds and the position of the hydroxyl group, resulting in a different receptor profile shown in the table below. These small structural differences determine why one cannabinoid intoxicates and the other two do not.

How does CBG act on the body?

CBG exhibits multi-directional pharmacological action, with the endocannabinoid system being one of many molecular targets. The 2022 review by Calapai et al. lists at least eight different mechanisms, including alpha-2 adrenergic agonism, 5-HT1A receptor modulation, anandamide reuptake inhibition, and TRPM8 channel blockade ([Calapai et al., MDPI Medical Sciences](https://www.mdpi.com/2076-3271/10/3/47), 2022).

CBG acts pharmacologically through at least eight molecular mechanisms, including strong alpha-2 adrenergic receptor agonism, partial 5-HT1A serotonin agonism, and anandamide reuptake inhibition ([Calapai et al., MDPI Medical Sciences](https://www.mdpi.com/2076-3271/10/3/47), 2022).

What are the potential therapeutic properties of CBG?

Most CBG studies come from in vitro and in vivo models, with very few clinical studies in humans. Nevertheless, CBG’s action profile is promising enough that Calapai et al. list potential applications in intestinal diseases, neurodegenerative diseases, bacterial infections, glaucoma, and cancers ([Calapai et al., MDPI Medical Sciences](https://www.mdpi.com/2076-3271/10/3/47), 2022).

Animal studies also indicate that CBG may lower intraocular pressure via the alpha-2 adrenergic mechanism - similar to clonidine used in ophthalmology for glaucoma treatment, though clinical studies in humans are lacking. Important disclaimer: none of the above properties can be declared as “medicinal” in the EU without appropriate registration approvals.

Does CBG have neuroprotective effects?

CBG’s neuroprotective profile is one of the most promising research areas. Valdeolivas et al. showed in 2015 that CBG delays neurodegeneration in two mouse models of Huntington’s disease, improving motor functions, protecting striatal neurons, and reducing mutant huntingtin aggregation ([Valdeolivas et al., Neurotherapeutics](https://pubmed.ncbi.nlm.nih.gov/25252936/), 2015).

In vitro studies also show CBG protects neurons from death caused by glutamate and hydrogen peroxide - effects potentially relevant for diseases like Alzheimer’s, Parkinson’s, or multiple sclerosis, though none of these studies have yet been validated in randomized clinical trials in humans. According to Calapai et al.’s review, by the end of 2021 about 90 papers on CBG were published, with less than 5% being clinical studies in humans - most evidence comes from cell lines and animal studies ([Calapai et al., MDPI Medical Sciences](https://www.mdpi.com/2076-3271/10/3/47), 2022). Thus, despite a promising profile, CBG remains at the stage of basic and early translational science - no doctor should currently recommend it as a substitute for evidence-based neurological treatment, and patients with neurodegenerative diseases should treat these results as directions for further research, not ready therapy.

How to use CBG and what are the doses?

There are no established official CBG doses for humans - cannabigerol is not a registered drug in Poland or the EU. Practical data come from producers’ experience, patient opinions, and cautious extrapolation from animal studies, not clinical trials in humans, so treat them as a starting point, not a fixed norm.

Standard 15% CBG oil contains 1500 mg CBG in a 10 ml bottle. One drop (approx. 0.05 ml) thus has about 7.5 mg CBG - at a daily dose of 30 mg, about 4 drops are needed, which at this volume lasts about 50 days. It is best to use the oil sublingually, holding it under the tongue for 60-90 seconds before swallowing, allowing absorption through the mucosa bypassing the liver.

Besides oils, other CBG forms are available: CBG flowers for vaporization or brewing, CBG capsules with slower but precise dosing, CBG cosmetics acting locally, and pet-friendly products for dogs and cats, which should always be consulted with a veterinarian. Regardless of form, start with a minimal dose (5-10 mg daily), observe the body’s reaction for 5-7 days, then gradually increase weekly - cannabinoid response is highly individualized.

15% CBG oil in a 10 ml package provides about 7.5 mg CBG per drop. At a typical dose of 30 mg daily, one bottle lasts about 50 days. There are no official registered CBG doses for humans - practical data come from producers’ and patients’ experience, not clinical studies.

Why are CBG oils more expensive than CBD oils?

The price of CBG oils directly results from plant biology. In typical cannabis strains, CBG constitutes less than 1% of dry mass, while CBD or THC can be 15-25%. To obtain 1 gram of CBG, a grower needs many times more plant biomass than for 1 gram of CBD - dedicated high-CBG strains are also more expensive to license than popular CBD strains ([Calapai et al., MDPI Medical Sciences](https://www.mdpi.com/2076-3271/10/3/47), 2022).

In Polish hemp stores, a typical 10% CBD oil usually costs 90-120 PLN per 10 ml (as of August 2026), while comparable CBG oils in 5-15% variants usually range around 100-240 PLN per 10 ml - 2-3 times more, reflecting raw material cost ratios. The second price factor is extraction: low CBG concentration in raw material requires more distillation cycles to achieve over 80% purity, increasing energy and labor costs. The third factor is COA certificates (Certificate of Analysis) - high-quality producers commission analyses in independent labs, adding a few PLN per bottle.

How to buy high-quality CBG oil?

This determines whether you buy a product matching the declaration: availability of a current certificate of analysis (COA) from an independent lab. The COA should include a full cannabinoid profile, purity tests (no heavy metals, pesticides, solvent residues), and an analysis date not older than 12 months. According to Calapai et al., lack of certification is one of the most common problems in the CBG market ([Calapai et al., MDPI Medical Sciences](https://www.mdpi.com/2076-3271/10/3/47), 2022).

On the Polish market, CBG is still a niche - a few brands offer full-spectrum oils with COA certificates, both Polish and foreign production. You can find the current oil offer in the store category, as availability of specific concentrations changes faster than this article’s content.

High-quality CBG oil should have a current COA certificate from an independent lab, including a full cannabinoid profile and tests for heavy metals, pesticides, and solvents. Check the analysis date before every purchase.

Is CBG legal in Poland?

Yes. CBG products are legal in Poland if the sum of delta-9-THC and tetrahydrocannabinolic acid (THCA) does not exceed 0.3% by dry mass - this is article 4 point 5 of the Act of July 29, 2005 on counteracting drug addiction (consolidated text Dz.U. 2023 poz. 1939), as amended by the Act of March 24, 2022 (Dz.U. 2022 poz. 763), effective from May 7, 2022. CBG itself is not a controlled substance in Poland or any EU country because it does not exhibit psychoactive effects.

Full-spectrum CBG oil may contain trace amounts of THC, but the producer must ensure that the sum of delta-9-THC and THCA does not exceed the 0.3% threshold by dry mass of the extract - COA tests confirm legal compliance. Broad-spectrum products and CBG isolates contain 0% THC. In the European Union, CBG is not classified as Novel Food in the same category as CBD, and the European Commission evaluates individual extracts case by case. Despite CBG’s legality, it is advisable to consult a doctor before starting use, especially if taking prescription drugs - more on this in the interactions section below.

CBG for animals: is it safe?

Pet-friendly CBG oils are a growing market segment, but scientific data are limited. Most is known about CBD in dogs and cats - studies show good tolerance at doses of 1-2 mg/kg body weight. For CBG, similar doses are extrapolated, though formal veterinary studies are still underway ([Calapai et al., MDPI Medical Sciences](https://www.mdpi.com/2076-3271/10/3/47), 2022).

Regardless of species, animal oil should be free of aromas and preservatives, and dosing should always be determined together with a veterinarian, not based on extrapolation from human doses.

CBG in cosmetics: how does it act on the skin?

CBG is gaining popularity in cosmetics due to two properties: antibacterial action against Staphylococcus aureus and anti-inflammatory effect via PPAR-γ receptor modulation. In the 2008 study by Appendino et al., CBG had MIC comparable to reference antibiotics against MRSA, making it an interesting ingredient for acne products ([Appendino et al., J. Nat. Prod.](https://pubmed.ncbi.nlm.nih.gov/18681481/), 2008). Cosmetic producers usually add it to serums and creams in small concentrations alongside other active ingredients, not as a standalone medicinal agent - keep this in mind when reading labels. We write more about hemp trends and ingredients in cosmetics in a separate review.

Does CBG interact with medications?

CBG, like other cannabinoids, is metabolized in the liver - including by the enzyme CYP2J2, which also participates in metabolism of some drugs and endogenous substances like anandamide ([Calapai et al., MDPI Medical Sciences](https://www.mdpi.com/2076-3271/10/3/47), 2022). Published clinical studies describing specific interactions of CBG with prescription drugs are still lacking - most data on cannabinoid-drug interactions concern CBD, not CBG, and should not be directly transferred.

Therefore, if you take medications regularly - especially anticoagulants, anticonvulsants, or psychiatric drugs - consult CBG use with your doctor or pharmacist before starting supplementation. The COA certificate confirms product composition but does not replace this conversation: it says nothing about how CBG will interact with a specific drug you already take. Caution is even more justified because CBG shares metabolic pathways with other cannabinoids for which drug interactions are better documented. The same applies to herbal supplements and other over-the-counter products - a doctor or pharmacist will assess risk more accurately than a product label or online user opinions.

The future of CBG research: what lies ahead?

Despite over 60 years since its discovery, CBG is still at an early stage of clinical research. According to ClinicalTrials.gov, in 2024 fewer than 20 clinical trials on CBG in humans were registered, compared to over 300 for CBD - most ongoing projects concern anxiety, depression, intestinal diseases, and chronic pain ([Calapai et al., MDPI Medical Sciences](https://www.mdpi.com/2076-3271/10/3/47), 2022).

Phase I studies evaluating safety and pharmacokinetics in healthy volunteers are underway in the USA, UK, and Israel, with preliminary results confirming a good safety profile of CBG at doses up to 200 mg daily. Phase II studies assessing efficacy in specific indications are only at a very early stage. Parallel research is developing synthetic CBG derivatives such as HU-433 or VCE-003.2 - molecules with increased receptor selectivity that may cause fewer side effects while maintaining therapeutic effect. Increasingly, studies also evaluate synergy of CBG with other cannabinoids and terpenes: Russo described in 2011 the so-called entourage effect, where the whole extract acts stronger than the sum of individual components ([Russo, Br. J. Pharmacol.](https://pubmed.ncbi.nlm.nih.gov/21749363/), 2011).

What myths circulate about CBG?

Many false claims about CBG circulate online, often spread for marketing purposes. According to the WHO ECDD critical review on CBD from 2018, a common problem in the hemp product market is declaring medicinal effects without scientific basis ([WHO ECDD, Cannabidiol Critical Review Report](https://www.who.int/publications/m/item/cannabidiol), 2018).

Frequently asked questions

Does CBG work immediately after taking it?

The duration depends on the form. Sublingual CBG oil works after 15-30 minutes, capsules after 60-90 minutes, and vaporizing CBG flower after 5-10 minutes. Vaporization gives the fastest effect, capsules the longest, but the effect lasts longest after capsules, about 6-8 hours.

Can I combine CBG with CBD?

Yes, and it is often recommended. Russo described in 2011 the entourage effect, where cannabinoids and terpenes mutually enhance each other’s effects ([Russo, Br. J. Pharmacol.](https://pubmed.ncbi.nlm.nih.gov/21749363/), 2011). Many producers offer ready-made CBG+CBD blends in 1:2 or 1:3 ratios, combining the properties of both compounds.

Is CBG detected in drug tests?

Standard drug tests look for THC and its metabolites, not CBG. Pure CBG isolate or broad-spectrum should not yield a positive result. Full-spectrum CBG oil may contain trace amounts of THC - with long-term use of high doses there is a theoretical risk of a positive result, though in practice it is low.

Does CBG cause side effects?

According to the review by Calapai et al., CBG has a good safety profile. The most commonly reported mild side effects are dry mouth, slight blood pressure drops, less often drowsiness and headaches. No reports of serious adverse effects at doses up to 100 mg daily ([Calapai et al., MDPI Medical Sciences](https://www.mdpi.com/2076-3271/10/3/47), 2022).

How does CBG differ from CBN?

CBN (cannabinol) forms from THC by oxidation and has mild sedative effects, so it is more often recommended for sleep. CBG is a precursor of THC and CBD, forms from CBGA, and acts rather stimulantly and focusing. They are completely different compounds despite similar names.

Does CBG help with sleep?

Directly, rather not - CBG acts more energizing and improves concentration, so for sleep CBD or CBN are better choices. Some users report that CBG reduces anxiety and tension, which may indirectly facilitate falling asleep, though there is no strong clinical evidence for this indication.

Can CBG be used during pregnancy?

No. There are no clinical studies in pregnant women, and all cannabinoids - THC, CBD, and CBG - are contraindicated during pregnancy and breastfeeding. This also applies to hemp cosmetics. Always consult such a decision with your attending physician.

Can I drive after taking CBG?

CBG itself does not affect driving ability because it is not psychoactive. However, full-spectrum oils may contain trace amounts of THC, so during roadside checks and very high doses there is a theoretical risk of a positive test. For safety, professional drivers should choose isolates or broad-spectrum oils without THC.

Summary: is it worth trying CBG?

CBG is a fascinating cannabinoid with a unique pharmacological profile - the “mother” of all other cannabinoids, non-psychoactive, with weak affinity to CB1 and strong to alpha-2 adrenergic receptors. In vitro and in vivo studies show promising potential in intestinal inflammation, bacterial infections, neurodegeneration, and glaucoma, but large clinical studies in humans are lacking - most evidence is still preclinical.

In Poland, CBG is legal if the sum of delta-9-THC and THCA does not exceed 0.3%, but its price remains 2-4 times higher than CBD due to low natural yield and extraction costs. If you are interested in CBG, start with a small dose (10-20 mg daily), choose a product with a current COA certificate, and consult your decision with a doctor - especially if you take medications regularly.

You can find the current assortment of CBG and CBD oils in the store category - stock and concentrations change continuously.

This article is for informational and educational purposes and does not constitute medical advice. Before starting cannabis or CBD for therapeutic purposes, consult a doctor, especially if you take other medications, are pregnant, or breastfeeding.

Author: Michał Waluk · Published: 2026-05-11 · Updated: 2026-08-10